Nanotechnology Characterization Laboratory

Metadata Updated: October 20, 2017

The Nanotechnology Characterization Laboratory (NCL) at the Frederick National Laboratory for Cancer Research performs preclinical characterization of nanomaterials intended for therapeutics and diagnostics developed by researchers from academia, government, and industry. NCL serves as a national resource and knowledge base for cancer nanomedicine developers and helps accelerate the development and translation of nanoscale particles and devices for clinical applications. For more info, please visit

Access & Use Information

Public: This dataset is intended for public access and use. License: No license information was provided. If this work was prepared by an officer or employee of the United States government as part of that person's official duties it is considered a U.S. Government Work.

Downloads & Resources


Metadata Created Date October 20, 2017
Metadata Updated Date October 20, 2017

Metadata Source

Harvested from Federal Laboratory Consortium Data.json

Additional Metadata

Resource Type Dataset
Metadata Created Date October 20, 2017
Metadata Updated Date October 20, 2017
Publisher Federal Laboratory Consortium
Unique Identifier 5BFBC8355C87453BE0530100007F29E9
Maintainer Email
Public Access Level public
Address1 P.O. Box B
Address3 P.O. Box B
Metadata Context
Schema Version
Catalog Describedby
Expertise NCL has over ten years of expertise in nanoparticle characterization. The lab has characterized more than 370 nano-based products for researchers worldwide and worked with 14 collaborators in clinical trials. Studies conducted at the NCL span the physicochemical, immunology, cancer biology, pharmacology, and toxicology fields. There are two main avenues for collaboration with the NCL: 1) Applying to NCL’s assay cascade characterization service for cancer nanomedicine 2) Initiating a Cooperative Research and Development Agreement (CRADA) for a specific research and development (R&D) need NCL’s Assay Cascade Through an application process, NCL offers preclinical characterization services to investigators who have developed promising nanotechnology-based cancer treatments. Once accepted, all characterization is performed at no charge to the submitting investigator. NCL uses a three-tiered assay cascade to thoroughly characterize each nanomaterial strategy submitted to the lab for physical and chemical attributes, in vitro biological properties, and in vivo compatibility through preclinical toxicology, pharmacology, and efficacy studies. Data generated from NCL can be used in partial support of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application with the FDA. Cooperative Research and Development NCL leverages its nanotech expertise to conduct sponsor-initiated R&D. Projects can include formulation, lead selection studies, assay development and instrument optimization, for example. Through work under contractor CRADAs, the lab has partnered with AstraZeneca and Amgen on reformulation projects and with Pfizer on the characterization of early nanotechnology platforms. NCL has expertise in formulation and characterization of an extensive variety of nanotechnology-based platforms, including polymeric, lipid-based, dendrimer, and inorganic nanoparticles.
Harvest Object Id 5f06132c-63d2-46a9-b7cc-a2f7571a5d08
Harvest Source Id 5859cfed-553c-48de-a478-b67b5225f6fc
Harvest Source Title Federal Laboratory Consortium Data.json
Phone 301-228-4874
Postalcode 21702-1201
Sizesqft 0
Source Datajson Identifier True
Source Hash 3a93224169c863a1d38bb8e7a89913dca683e8c4
Source Schema Version 1.1

Didn't find what you're looking for? Suggest a dataset here.